The Office of the U.S. Food and Drug Administration (FDA) that was responsible for cancer therapy approval gets renamed as the Office of Oncologic Diseases (OOD), and it's been restructured to add new divisions. 

The new Divisions are DO1, for breast, gynecologic and genitourinary cancers; DO2, for thoracic and head and neck cancers; DO3, for gastrointestinal malignancies, melanoma, and other advanced skin cancers. The other divisions are Division of Hematologic Malignancies 1 (DHM1), Division of Hematologic Malignancies 2 (DHM2), and Division of Hematology Oncology Toxicology (DHOT).